Figures & data
Table 1 Background data and glycemic and lipid parameters (before changing basal insulin analogs) for 73 patients with T1DM treated with a long-acting insulin analog (detemir or glargine) for 12 to 24 months
Table 2 Details of insulin treatment regimens prior to changing basal insulin from NPH to detemir or glargine
Figure 1 Mean change from initial to last observation for 73 patients with T1DM treated with insulin detemir (n = 30; mean duration of observation, 18 months) and glargine (n = 43; mean duration of observation, 18 months) in a) weight (kg) and HbA1c (%) and b) bolus- and long-acting insulin dosages. Bars indicate mean and standard error. *p < 0.05 from baseline.
Table 3 Half-yearly changes in insulin dosage, HbA1c and proportion of T1DM patients receiving insulin once daily, over 24 months of treatment with either insulin detemir or glargine